FDA Approves AstraZeneca First-in-Class Inhaler for Asthma

The FDA has approved AstraZeneca’s Airsupra (albuterol and budesonide) metered-dose inhaler as the first asthma rescue inhaler to treat both symptomatic exacerbation and underlying inflammation in adults 18 years and older.

The FDA approval is based on phase 3 trials that showed reduced risk of severe asthma exacerbations for patients with moderate to severe asthma and improved lung function for those with mild to moderate asthma.

The drug-device combination product is the result of a March 2018 collaboration deal between AstraZeneca and Avillion.